Patients with NHL and CLL in B cell-directed therapies respond poorly to COVID-19 mRNA vaccination
Especially patients with non-Hodgkin lymphomas and chronic lymphocytic leukemia (CLL) who are actively treated with or have received B cell-directed therapies have failed to produce anti-spike antibodies despite full courses of COVID-19 mRNA vaccination. In this MEDtalk, MD Shipra Goel, Infectious diseases, Roswell Park Comprehensive Cancer Center, Buffalo, New York presents updated results of a study looking at factors that may predict adequate response to COVID-19 vaccines.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.